Investigational Drug Information for Geldanamycin
✉ Email this page to a colleague
What is the development status for investigational drug Geldanamycin?
Geldanamycin is an investigational drug.
There have been 15 clinical trials for Geldanamycin.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2004.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, and Biogen.
Summary for Geldanamycin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,653 |
| WIPO Patent Applications | 2,870 |
| Japanese Patent Applications | 42 |
| Clinical Trial Progress | Phase 2 (2004-07-01) |
| Vendors | 86 |
Recent Clinical Trials for Geldanamycin
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma | Esanex Inc. | Phase 1 |
| Dose Escalation of IPI-493 in Hematologic Malignancies | Infinity Pharmaceuticals, Inc. | Phase 1 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Geldanamycin
Top disease conditions for Geldanamycin
Top clinical trial sponsors for Geldanamycin
US Patents for Geldanamycin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
